A phase II open-label, multi-centre, randomised, prospective, parallel-group study comparing Topotecan/Carboplatin administered 5 days versus 3 days versus Topotecan monotherapy daily x 5 as second line treatment for patients with relapsed extensive disease small cell lung cancer.

Trial Profile

A phase II open-label, multi-centre, randomised, prospective, parallel-group study comparing Topotecan/Carboplatin administered 5 days versus 3 days versus Topotecan monotherapy daily x 5 as second line treatment for patients with relapsed extensive disease small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2011

At a glance

  • Drugs Topotecan (Primary) ; Carboplatin
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Top Challenge
  • Most Recent Events

    • 22 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top